Prognostic Biomarkers for Response to Vascular Endothelial Growth Factor-Targeted Therapy for Renal Cell Carcinoma Review uri icon


MeSH Major

  • Carcinoma, Renal Cell
  • Kidney Neoplasms
  • Molecular Targeted Therapy
  • Vascular Endothelial Growth Factor A


  • Improved understanding of renal carcinoma disease biology has led to the discovery and approval of five novel therapies targeting specific molecules in the vascular endothelial growth factor (VEGF) biochemical pathway. Biomarker studies attempting to predict response to VEGF-targeted therapies have largely focused on circulating proteins, tissue-based molecules, and germline polymorphisms. Thus far studies have yielded conflicting results that require prospective validation; therefore no definitive biomarker has yet been integrated into the clinician's armamentarium. However, early analyses featuring genomic biomarkers have generated promising findings. This article provides an overview of available biomarkers evaluated with respect to VEGF-targeted therapies in patients with advanced renal cell carcinoma.

publication date

  • February 2016



  • Review



  • eng

PubMed Central ID

  • PMC4864362

Digital Object Identifier (DOI)

  • 10.1016/j.ucl.2015.08.009

PubMed ID

  • 26614032

Additional Document Info

start page

  • 95

end page

  • 104


  • 43


  • 1